 |
Prospector
Profile
1107-08
|
| |
| Bioenvision, Inc. |
NAICS |
541710 |
| 345 Park Avenue 41st Floor
New York, NY 10154 |
Description |
Biotechnology |
| (212) 750-6700 |
Employees |
32 |
| http://www.bioenvision.com/ |
Revenue |
(mil) |
19.0690 |
| |
Income |
(mil) |
-35.9040 |
| |
Assets |
(mil) |
69.9730 |
| |
Liability |
(mil) |
19.7850 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Bioenvision, Inc. had a net loss of $36,242,081 on revenues of $19,069,597 for the year ended June 30, 2007. This is much higher than the $24,236,263 net loss on $5,309,072 in revenues reported during the year ended June 30, 2006, and the $24,666,864 net loss on $4,651,174 in revenues incurred during the year ended June 30, 2005. As a result of its recurring losses, the Company's balance sheet showed an accumulated deficit of $122,809,349 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company is the exclusive licensee or sublicensee of three U.S. patents relating to compounds, pharmaceutical compositions and methods of use encompassing clofarabine. It has also filed two U.S. patent applications relating to the use of clofarabine in autoimmune diseases. Although the composition of matter patents to trilostane have expired, the Company is the exclusive licensee of several U.S. and foreign patent applications relating to the use of trilostane alone or in combination with anticancer agents and the exclusive licensee to a manufacturing process patent for trilostane. In addition, the Company has international process and use patent applications filed for Gene Therapy which will expire in April 2018. For OLIGON®, the Company has process, use and composition of matter patents in the U.S. and internationally and a patent application in Japan. [SEC Filing 10-K 09-12-07]
|
| |
|
Description:
The biopharmaceutical company focuses on the acquisition, development, and marketing of compounds and technologies for the treatment of cancer.
|
| |
|
Officers:
Christopher B. Wood (Chair & CEO); James S. Scibetta (CFO); Kristen M. Dunker (VP & Gen. Counsel); MaryJane Rafii (VP); Robert Sterling (VP); Thomas S. Nelson (Dir.); Michael Kauffman (Dir.); Joseph Cooper (Dir.)
|
| |
|
Auditor:
JH Cohn LLP
|
| |
|
Securities:
Common Stock-Symbol BIVN; Nasdaq;
55,037,771 common shares outstanding as of September 5, 2007.
|
| |
| |
| |
| return to main page |
|
|
